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Abstract
Purpose—About 60% of ovarian cancers are diagnosed at late stage, when 5-year survival is less 
than 30% in contrast to 90% for local disease. This has prompted search for early detection 
biomarkers. For initial testing, specimens taken months or years before ovarian cancer diagnosis 
are the best source of information to evaluate early detection biomarkers. Here we evaluate the 
most promising ovarian cancer screening biomarkers in prospectively collected samples from the 
European Prospective Investigation into Cancer and Nutrition study.
Experimental Design—We measured CA125, HE4, CA72.4 and CA15.3 in 810 invasive 
epithelial ovarian cancer cases and 1,939 controls. We calculated the sensitivity at 95% and 98% 
specificity as well as Area under the Receiver Operator Curve (C-statistic) for each marker 
individually and in combination. Additionally, we evaluated marker performance by stage at 
diagnosis and time between blood draw and diagnosis.
Results—We observed the best discrimination between cases and controls within six months of 
diagnosis for CA125 (C-statistic=0.92), then HE4 (0.84), CA72.4 (0.77), and CA15.3 (0.73). 
Marker performance declined with longer time between blood draw and diagnosis and for earlier 
staged disease. However, assessment of discriminatory ability at early stage was limited by small 
numbers. Combinations of markers performed modestly, but significantly better than any single 
marker.
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Conclusions—CA125 remains the single best marker for the early detection of invasive 
epithelial ovarian cancer, but can be slightly improved by combining with other markers. 
Identifying novel markers for ovarian cancer will require studies including larger numbers of early 
stage cases.
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ovarian cancer; CA125; HE4; CA15.3; Ca72.4
Introduction
Ovarian cancer generally does not exhibit specific early symptoms. About 60% of ovarian 
cancers are diagnosed at late stage, which is associated with a 5-year survival of less than 
30%, contrasted with more than 90% survival for disease found locally (1). This has 
prompted extensive research to find early detection biomarkers for ovarian cancer.
Many potential serum biomarkers for ovarian cancer have been indentified (2). Candidate 
biomarkers are often first identified from preclinical studies using immunohistochemical 
testing or gene expression profiles of tumor tissue. These are called Phase I studies (3). 
Potential biomarkers are then tested by comparing blood from cases at diagnosis of ovarian 
cancer with blood from either women with benign disease or healthy controls. This type of 
study has been described as a Phase II study. Markers that have been approved using Phase 
II data include CA125, HE4, and a panel of markers, including prealbumin, apolipoprotein 
A-1, β2-microglobulin, and transferrin (4, 5). CA125 has been approved for disease 
monitoring (6), and HE4 and a panel of markers as tools for distinguishing benign from 
malignant pelvic masses (4, 5). Phase III data refers to studies based on blood samples from 
asymptomatic women taken months or years prior to a diagnosis of ovarian cancer, while 
phase IV data refers to markers tested in a clinical trial in which asymptomatic women are 
randomized to a screening arm or to usual care.
There have been three randomized trials of screening for ovarian cancer using either CA125 
alone or CA125 in combination with transvaginal ultrasound (TVUS). No reduction in 
ovarian cancer mortality was observed in the Prostate, Lung, Colorectal, and Ovarian cancer 
(PLCO) screening trial, based on a combination of TVUS and CA125 measurements for 
four years and two additional years of CA125 measurements (7). However, recent results 
from the UKCTOCs study showed a 15% reduction in mortality for postmenopausal women 
followed for change in CA125, which was marginally significant (8). One additional 
randomized trial in Japan (9) showed a nonsignificant increase in early stage tumors detected 
in the screening arm but did not follow participants for mortality (9). To date, neither CA125 
nor TVUS have been approved or recommended for screening on the basis of the 
randomized trials.
Although selected specimens from the Phase IV studies may be and have been used in the 
context of discovering and testing new biomarkers, they may not be ideal for this purpose for 
at least two reasons. First, since CA125 was the primary screening tool, this may lead to 
preferential selection of CA125-expressing tumors. Second, since annual screening was 
employed, the natural history of the disease may have been interrupted at early stages and 
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may not provide a true measure of the lead time, i.e. the time between early diagnosis with 
screening and when diagnosis would have occurred in the absence of screening. Therefore, 
samples collected in asymptomatic women before cancer diagnosis are needed to test new 
biomarkers. To date, only a few case-control comparisons have been made in prospectively 
collected specimens obtained in asymptomatic women before clinical cancer diagnosis 
under usual care (Phase III studies) (10-12). Both the Carotene and Retinol Efficacy Trial 
(CARET) and Women's Health Initiative (WHI) studies were designed as randomized trials 
to evaluate other disease outcomes but have the advantage of closely monitoring a large 
group of women with banked blood samples. In the CARET study, a panel of markers 
including CA125, HE4, mesothelin, B7-H4, DcR3, and spondin-2 were measured on serial 
samples from 34 women with ovarian cancer and 70 matched controls. Of these, only 
CA125 and HE4 showed significant differences between cases and controls and had modest 
discriminatory ability that waned with increasing time between blood draw and diagnosis. 
Similarly in the WHI study, CA125 and HE4 were measured in 353 ovarian cancer cases and 
1,261 healthy controls and these markers significantly improved a risk prediction algorithm 
based on epidemiologic factors (11).
Here, we present results from a Phase III study using serum samples from the EPIC cohort 
(European Prospective Investigation into Cancer and Nutrition). We measured CA125, 
CA15.3, HE4 and CA72.4 in 197 cases of ovarian cancer diagnosed within the first three 
years after blood donation and 724 matched control subjects. For 613 additional ovarian 
cancer patients diagnosed more than 3 years after blood draw, and for 1,215 additional 
control subjects, we extended the measurements of CA125 and CA15.3 for examination of a 
possible longer-term risk diagnostic prediction capacity of these markers and to allow more 
accurate analyses of possible relationships of these markers with epidemiologic risk factors 
for ovarian cancer. The objectives of our analyses were: (i), to examine the early detection 
capacity of our biomarker panel for ovarian cancer diagnoses within comparatively short 
time intervals (variable lag time strata ≤3 years between blood donation and diagnosis); (ii), 
to examine the capacity of CA125 and CA15.3 to predict ovarian cancer risk over a longer 
term (>3 years between blood donation and diagnosis); and (iii), to examine whether early 
diagnostic capacity or longer-term risk prediction by the biomarkers could be improved by 
integrating further information about a woman's general epidemiologic risk factor profile.
Materials and Methods
The EPIC cohort – background and collection of blood samples
The European Prospective Investigation into Cancer and Nutrition is an ongoing multicenter 
prospective cohort study designed to investigate the relationship between diet, nutrition and 
metabolic factors with cancer. Descriptions of study design, population and baseline data 
collection of the cohort have been reported in detail previously (13, 14). In brief, 519,978 
participants (366,521 women) were enrolled from 1992 to 2000 in 23 centers in 10 European 
countries: Denmark, France, Germany, Greece, Italy, Norway, the Netherlands, Spain, 
Sweden, and the United Kingdom. For women, the age range at recruitment was mostly 
between 35 to 70 years. At baseline, comprehensive data on diet, lifestyle, reproductive and 
menstrual factors, current and past use of exogenous hormones (oral contraceptives [OC] 
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and postmenopausal hormone replacement therapy [HRT]) and medical history were 
collected through standardized questionnaires. In addition, anthropometric measures were 
obtained.
A total of 385,747 study participants in the EPIC cohort (226,673 women and 159,074 men) 
also provided a baseline blood sample. In France, the Netherlands, the United Kingdom, 
Germany, Spain, Italy and Greece blood samples were collected according to a standardized 
protocol (15). From each study participant, about 30 ml of blood were drawn, and serum, 
plasma, erythrocytes and buffy coat were aliquoted in 28 plastic straws of 0.5 ml each, 
which were heat-sealed and stored under liquid nitrogen (−196°C). In Denmark, blood 
fractions were aliquoted into 1-ml tubes, and stored in the vapor phase in liquid nitrogen 
containers (−150°C). In the Swedish Center of Umeå, blood samples were divided into 10 
aliquots of 1.5-mL each: 6 plasma, 2 buffy-coat and 2 erythrocytes, which were rapidly 
frozen at −80°C in standard freezers.
Ascertainment of incident cancer cases
Prospective follow-up for cancer occurrences and histologic confirmation was performed 
through record linkage with cancer and pathology registries (all countries except France, 
Germany and Greece) or through active follow-up and systematic verification of self-reports 
by detailed examination and coding of clinical records. In all countries, vital status was 
determined by regular linkages with population and mortality registers at the regional or 
national level.
At the time the present study was initiated, prospective follow-up was complete until the end 
of 2005 (France) to 2008 (Germany). Within this timeframe, and among those women who 
had provided a baseline blood sample, a total of 810 incident invasive cases of ovarian 
cancer had been identified. Case subjects were defined as women who developed incident 
epithelial invasive ovarian (ICD code: C569), fallopian tube (C570) or peritoneal cancer 
(C480, C481, C482, C488) after recruitment into the EPIC study according to the 
International Classification of Diseases for Oncology (ICD) 0–3 and with data on tumor 
histology.
More detailed information on tumor characteristics (histologic subtype [serous, 
endometrioid, clear cell, mucinous, not otherwise specified (NOS), grade [well, moderately 
or poorly/undifferentiated] and stage [local, regional, metastatic]) were obtained from 
pathology reports and from cancer registries. For the 810 invasive ovarian cases, complete 
information on tumor grade was available for 473 patients (58%) and information on tumor 
stage was available for 712 patients (88%). Well differentiated tumors were classified as low 
grade; moderately and poorly/undifferentiated tumors were classified as high grade. We 
classified cases with local disease (stage I) as low stage and cases with regional (stage II) or 
metastatic disease (stage III/IV) as high stage.
Design of nested case-control study
For each case subject up to four control subjects were randomly selected among appropriate 
risk sets consisting of all female cohort members with a blood sample, alive and free of 
cancer at the time of diagnosis of the index case. An incidence density sampling protocol 
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was used, such that, in principle, control subjects could include study participants who 
became a case later in time and each control subject could be sampled more than once – the 
control subjects actually drawn, however, did not include any of the future cases of ovarian 
cancer detected so far in the EPIC cohort. Case and control subjects were matched on study 
recruitment center, age at blood donation (±6 months), time of the day of blood collection 
(±1 h), fasting status (<3 h, 3–6 h, >6 h), follow-up time, and menopausal status at blood 
collection (premenopausal, perimenopausal, postmenopausal), current use of exogenous 
hormones (oral contraceptives, HRT) at the time of blood draw, as well as menstrual cycle 
phase for premenopausal women (3-5 categories, depending on available data). Cases 
missing data on phase of menstrual cycle were matched to control subjects whose 
information on menstrual cycle phase was also missing.
Informed consent and data protection
All participants had given their consent for future analyses of their blood samples and the 
present study was approved by the IARC Ethics Committee and the Institutional Review 
Board of Brigham and Women's Hospital.
Laboratory assays
Measurements of the protein levels of CA125, CA15.3, HE4 and CA72.4 were completed 
for a total of 197 incident cases of invasive ovarian cancer and 725 matched, cancer-free 
control subjects. Additionally, we measured CA125 and CA15.3 in 613 cases with invasive 
ovarian cancer who had been diagnosed more than three years after blood donation, and 
1,214 additional matched control subjects. Laboratory values were missing for CA125 (3 
cases, 12 controls), CA15.3 (6 cases, 19 controls), HE4 (2 controls), and CA72.4 (2 
controls) due to lack of sufficient sample volume. All measurements were performed in the 
Genital Tract Biology Laboratory following pre-analytic, analytic and post-analytic SOPs 
established under the lab's accreditation by the College of American Pathologists, using a 
volume-effective highly sensitive multiplex platform (Meso Scale Discovery, MSD) based 
on electrochemo-luminiscence (ECL) detection. Human CA125 (catalog number K151WC) 
and Human Prototype CA15.3 (catalog number N45ZA-1) were provided by MSD in 
singleplex assays. The linearity range for CA125 was 10,000-0.6 U/ml, and for CA15.3 was 
12,500-0.19 mU/ml. The HE4 and CA72.4 measurements were done in a custom designed 
duplex assay. The following reagents were a gift from Fujirebio Diagnostics, Inc. (Malvern, 
PA): IgHE4 antigen, which we used to generate a calibration curve with a linear range 
starting at 3600 pM; anti-HE4 capture IgG1 (2H5 mouse hybridoma, Fujirebio catalog 
number 414-01S); anti-HE4 detection IgG1 (mouse hybridoma 3D8, Fujirebio catalog 
number 415-01); TAG72 Defined Antigen, which we used to generate a calibrator curve 
with a linear range starting at 2400 U/ml; anti-72.4 capture IgG1 (mouse hybridoma CC49, 
Fujirebio catalog number 110-005); anti-CA72.4 IgG1 (mouse hybridoma B72.3, Fujirebio 
catalog number 110-000). The samples were split into batches such that matched case-
control sets and samples from the same study center were kept together in the same batches. 
The samples were tested undiluted in the CA125 singleplex and the HE4/CA72.4 duplex, 
and they were tested at a 50-fold dilution in the CA15.3 assay. A quality control pool was 
prepared from serum samples from ovarian cancer patients with within linearity range levels 
of each protein and split into equal aliquots. To establish inter-plate variability, one aliquot 
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of this pool was tested at multiple dilutions spanning the linearity range of each assay, three 
dilutions run in duplicates and two dilutions run in triplicates, providing up to six quality 
control data points in each assay plate. In addition, blinded, randomly chosen citrated 
plasma, EDTA plasma, and serum Blood Bank samples were split into aliquots (128 for 
CA125, 130 for CA15.3, and 104 for HE4/CA72.4) and distributed within and between 
plates. Coefficients of variation (CV) were calculated as 100*SD/mean. The unblinded 
quality control sample pool repeatedly tested on every assay plate showed the following 
interplate CV and min-max range (mean) of intraplate CV: 1) CA125, 8.4% interplate CV 
and 0.2-13.5% (3.4%) intraplate CV; 2) CA15.3: 15.4% interplate CV and 0.5-6.1% (2.3%) 
intraplate CV; 3) HE4: 8.99% interplate CV and 1.6-7.6% (3.6%) intraplate CV; 4) CA72.4: 
17.3% interplate CV and 0.9-13% (5.5%) intraplate CV. Similarly, the blinded aliquots with 
values within the linearity range of each assay showed the following interplate CVs and min-
max (mean) intraplate CVs: 19% and 3-20% (9%) for CA125, 22% and 3-5% (4%) for 
CA15.3, 9% and 4-10% (6%) for HE4, 16% and 1-16% (6%) for CA72.4. Since the majority 
of the blinded aliquots for CA72.4 fell below the lower limit of detection, blinded CA72.4 
CVs were based on the remaining 13 aliquots, ranging in CA72.4 value from 1.15 to 1.87 
U/mL.
Statistical analyses
First, we evaluated the distribution of each biomarker for normality and outliers. As 81% of 
the samples had CA72.4 values below the lower limit of detection for this assay (1.119 U/
mL), we assigned these values to the midpoint between zero and the lower limit of detection 
for future analyses. Other markers assessed did not have any values below the lower limit of 
detection. Locally estimated scatterplot smoothing (LOESS) curves were used to describe 
mean levels of each marker among cancer cases and control subjects at different lag-times 
until ovarian cancer diagnosis. The discrimination between cases and control subjects was 
described using receiver operating characteristic (ROC) curves, with the area under curve, 
also known as the C-(concordance) statistic, as an overall measure for discrimination 
capacity. We estimated the diagnostic sensitivities (SE95 and SE98, respectively) of each 
marker at cut-points corresponding to 95% and 98% specificity, determined in our full 
dataset for all control subjects (N = 1,939 for CA125 and CA15.3; N= 725 for HE4 and 
CA72.4).
The diagnostic sensitivity, specificity and C-statistics were calculated for risk scores based 
on the associations between biomarker levels and ovarian cancer risk, overall and by strata 
of lag-time between blood donation and cancer diagnosis, conditional logistic regression 
models were used, accounting for the matched study design. Models were fitted for 
continuous biomarker measurements after log2-transformation, to achieve approximate 
normality of their distributions. Basic analyses focused on single markers. Additional 
multivariate models were developed to examine the discrimination capacity of multiple 
markers in combination, and of markers combined with an epidemiologic risk prediction 
algorithm, including age at menopause, duration of hormone replacement therapy, body 
mass index, unilateral ovariectomy, duration of oral contraceptive use, and number of full-
term pregnancies that we developed previously on the basis of the full EPIC cohort data 
(16).
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To examine how the early detection and/or risk prediction capacities of the biomarkers 
changed with time between blood draw and clinical cancer diagnosis, all analyses were 
performed within variable strata of lag-time (≤6 months, ≤12 months, 1-2 years, 2-3 years, 
3-6 years, >6 years). To examine heterogeneity of diagnostic prediction capacity by tumor 
stage at diagnosis or by histologic tumor sub-types, likelihood-ratio tests were used 
comparing the model fit for logistic regression models with and without corresponding 
interaction terms. For all risk models, the discrimination between cases and control subjects 
was described using ROC curves.
For multi-marker discrimination models, the statistical fit of nested models was compared 
with likelihood-ratio tests, and bootstrapping methods were used to correct for model 
overfitting and over-optimism in the estimation of discrimination capacity. Additionally, 
measures of continuous net reclassification improvement were calculated, which represents 
the percent of case and control subjects correctly re-classified as a result of the added marker 
(17). Analyses were conducted in SAS (version 9.3, SAS Institute, Cary, NC, USA).
Results
Baseline characteristics of ovarian cancer case patients by tumor characteristics are 
presented in Table 1. Of the 810 case patients examined in this study, 752 (93%) had the 
ovary classified as primary tumor site, whereas in 33 (4%) the primary site was the fallopian 
tube and in 25 patients (3%) it was the peritoneum. More than half of the tumors (55%) were 
of serous histology (n = 445), 12% endometrioid (n = 96), 7% mucinous (n = 58), 5% other 
(malignant epithelial neoplasms, carcinoma, malignant mixed Müllerian or malignant 
Brenner tumors; n = 38), 4% clear cell (n = 37), and 17% not otherwise specified (NOS) (n 
= 136). Of the 712 case subjects with information about tumor stage at diagnosis, 115 were 
classified as stage I, 128 as stage II and 469 as stage III and higher (stage III/IV). Compared 
to case patients diagnosed at stage II and higher, there was a relative over-representation of 
mucinous, clear cell and endometrioid tumors among the stage I patients, whereas serous 
tumors were predominantly represented among the patients with cancer in stage II and 
higher (see Supplementary Table S1). Overall, the median age at cancer diagnosis was 62.7 
years (range: 30.6 – 86.5 years), and varied according to the histologic subtypes 
(Supplementary Table S1).
Visual inspection of locally estimated scatterplot smoothing (LOESS) curves suggests that 
none of the biomarkers were increased over normal (control) values earlier than about two 
years prior to diagnosis, and more than 6 months prior to diagnosis increased levels were 
discernable only for case patients who were diagnosed with ovarian cancer at advanced stage 
(stage II or III) (Figure 1).
For the pre-defined variable lag times between blood donation and date of diagnosis, the 
ability of the early detection markers to discriminate between case patients and control 
subjects is indicated by C-statistics and estimated sensitivities at specificity cut-points of 
95% (SE95) and 98% (SE98) (Table 2). In addition, receiver operator characteristic (ROC) 
curves are shown in Figure 2. For blood samples taken ≤6 months prior to diagnosis, the 
highest C-statistic was observed for CA125 (C=0.92), followed by HE4 (C=0.84), CA72.4 
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(C=0.77) and CA15.3 (C=0.73). Correspondingly, within the first 6 months, values for SE95 
and SE98 were fairly high for CA125 (0.81 and 0.77, respectively) and HE4 (0.67 and 0.59), 
and modest for CA72.4 (0.56 and 0.37) and CA15.3 (0.31 and 0.23). For all markers, the 
capacity to discriminate between future case patients and non-cases dropped rapidly with 
increasing time lags between blood donation and tumor diagnosis (Table 2, Figure 2). For 
example, for a time lag between 1 and 2 years, C-statistic values were 0.72 for CA125, 0.65 
for HE4, 0.61 for CA72.4 and 0.52 for CA15.3. At time lags between 3 and 6 years, the two 
markers that were tested for longer-term prediction of ovarian cancer, CA125 and CA15.3 
had C-statistics of only 0.55 and 0.53, respectively (Table 2).
Within the first 12 months after blood donation, for all markers except CA15.3 the ability to 
predict future cancer diagnosis was clearly stronger for advanced tumors (stage II and 
III/IV) and relatively weak for stage I tumors (Supplementary Figure 1), and this 
heterogeneity was statistically significant for CA125 and HE4 (phet < 0.05; Table 2). 
Regarding tumor histology, CA125, HE4 and CA72.4 showed fairly strong discrimination of 
serous ovarian cancer patients from their matched controls, especially within short lag-times 
after blood donation (Supplementary Table S2); for the other histologic subtypes, the 
numbers of patients were too small to obtain reliable estimates.
Among the control subjects, no meaningful correlations between markers were observed (r = 
−0.15 to 0.18). Among the case subjects only, and especially among those with lag-times 
since blood donation below 1 or 2 years, moderately strong correlations were observed 
between CA125, HE4 and CA72.4 (e.g., within 1-year's lag-time: r = 0.23 to 0.74), whereas 
CA15.3 showed somewhat weaker associations with the other markers (within 1-year's lag-
time: r = 0.11 to 0.24) (Supplementary Table S3).
In a stepwise forward selection strategy, focusing on variable lag-time strata within the first 
3 years after blood donation, the overall model fit for a logistic risk model improved 
statistically significantly with successive additions of CA125, HE4, CA72.4 and CA15.3 as 
pre-diagnostic predictors of future ovarian cancer diagnosis, although the statistical 
significance for CA15.3 was lowest and largely restricted to lag-times less than 6 months 
(Table 3). However, the overall improvements in the overall discrimination, assessed by C-
statistic (Table 3) or NRI (Supplementary Table S4), were small compared to a model 
based on any of the markers CA125, HE4 or CA72.4 alone.
Finally, we examined whether the overall discrimination between case patients and control 
subjects could be improved by combining the biomarkers with an epidemiologic 
stratification algorithm that was developed previously using the full EPIC cohort data (16). 
Because some of the key epidemiologic risk variables included in the algorithm (age, 
menopausal status, use of oral contraceptives or hormone replacement therapy [HRT]), 
overlapped with some of the matching factors for the present nested case-control study, the 
risk model showed a lower discrimination (C = 0.56) in our case-control set as compared to 
our previous full cohort analysis (corrected for over-optimism, C = 0.64). For lag-times 
below 2 years, combining the risk model with the biomarkers did not improve overall 
discrimination as compared to each of the biomarkers alone (results not shown). By contrast, 
for lag times greater than 3 years, the longer-term prediction of future ovarian cancer 
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diagnosis was moderately but significantly improved when CA125 was added to the model 
(C=0.57 vs. C=0.55), whereas adding CA15.3 showed no improvement.
Discussion
In our evaluation of four potential ovarian cancer screening biomarkers measured in 
prospectively collected samples from women with ovarian cancer and matched controls in 
the EPIC cohort, we observed the best sensitivity and specificity for CA125, followed by 
HE4, CA72.4, and finally CA15.3. The ability of these biomarkers to distinguish cases from 
controls declined with increasing time between blood draw and diagnosis, as well as with 
earlier stage at diagnosis. These observations suggest that, generally, these markers are best 
at identifying advanced disease close to diagnosis, but their ability to detect early disease 
that is amenable to interventions that can improve survival may be limited. Addition of a 
previously established risk prediction model did not improve the performance of markers in 
women who went on to develop clinically manifest ovarian cancer less than three years in 
advance of diagnosis. By contrast, adding CA125 (but not CA15.3) to the risk prediction 
model did slightly improve the longer-term prediction of ovarian cancer occurrence over a 
time interval of about 3 to 6 years after blood donation.
Our results are consistent with those from large randomized trials and prospective 
assessments of these markers in other populations. All four of these biomarkers were 
included in an ancillary study of 49 biomarkers previously evaluated in Phase II studies, and 
all four were also among the best 35 that were subsequently examined within the prospective 
PLCO cohort (18). Results from the PLCO study were similar to what we observed in EPIC, 
with the best performance in cases diagnosed six months or less after blood draw (depending 
on the time between blood draw and diagnosis), C-statistics ranged from 0.83-0.96 for 
CA125, 0.78-0.88 for HE4, 0.80 for CA72.4, and 0.72 for CA15.3. As in our present study, 
the discriminatory ability of these markers in the PLCO cohort declined rapidly for samples 
collected more than six months prior to diagnosis. An important difference between PLCO 
and our study, however, is that PLCO participants had been annually screened for ovarian 
cancer by CA125 plus ultrasonography, thereby reducing the occurrence of further ovarian 
cancer diagnoses over time periods longer than 12 months. In another prospective study, 
Anderson and colleagues measured CA125 and HE4 among other markers in a total of 34 
incident cases of ovarian cancer who had provided serial blood samples up to 18 years prior 
to diagnosis and noted a similar decline in marker performance over time with an AUC at <2 
years of 0.74 and 0.71 and from 2-4 years of 0.68 and 0.67 for CA125 and HE4, respectively 
(10).
The ultimate goal of screening is to identify cancer at a stage at which medical intervention 
has the highest chances of providing a cure or prolonging survival. None of the four markers 
that we tested showed a clear capacity for predicting disease that was diagnosed in stage-I, 
even for follow-up times of less than 6 months. This finding, however, may have been 
confounded by tumor histology, as among patients diagnosed with stage-I disease, there was 
an over-representation of mucinous and clear cell tumors, which are generally slowly 
growing tumor sub-types and diagnosed at earlier stages. By contrast, within less than 12 
months of prospective follow-up especially CA125 and HE4 showed substantial 
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discriminatory capacity for tumors that had been subsequently diagnosed at a more advanced 
stage, and the discrimination of these markers was also significantly stronger for the more 
aggressive type-II tumors as compared to type-I tumors. A major limitation of prospective 
studies such as EPIC and PLCO is that they do not inform about a patient's tumor stage at 
the time of blood donation; hence, no direct information is available whether those women 
whose tumor might have been diagnosed 6-12 months before clinical diagnosis through 
CA125 or HE4 screening would have actually shown a sufficient shift towards an earlier 
tumor stage to allow speculations about significant improvements in survival.
Despite having the best performance among various candidate markers considered for 
ovarian cancer screening in various studies (10, 18, 19), annual CA125 measurement 
(combined with transvaginal ultrasound) in the PLCO randomized trial showed no mortality 
benefit (7). This lack of benefit is likely related to insufficient sensitivity of a single CA125 
measurement for detecting the more aggressive forms of ovarian cancer in an early stage of 
disease, as suggested by the findings in both PLCO and our study. However, several studies 
have shown that the use of serial measurements over time can improve the diagnostic 
performance for ovarian cancer detection (20-23). In the world's largest ongoing, 
randomized screening trial for ovarian cancer – the United Kingdom Collaborative Trial on 
Ovarian Cancer Screening (UKCTOCS) – consideration of change in CA125 over time 
using the ROCA algorithm improved marker performance from C-statistic = 0.87 for a 
single CA125 to C = 0.92 and doubled the number of screen-detected invasive epithelial 
ovarian cancers compared to CA125 screening with a fixed cutoff (22). Furthermore, recent 
mortality results from the UKCTOCs revealed a 15% reduction in mortality for women 
screened using the ROCA algorithm among incident cases (p=0.02) (8).
Results from various Phase II and other clinical studies have suggested that combinations of 
multiple biomarkers may be better at distinguishing malignant from benign tumors than 
CA125 alone. For example, improved discrimination has been documented for the 
combination of CA125 and HE4 – the two strongest discriminating biomarkers in our 
analyses – as compared either marker alone (12, 24-31). While our analyses confirm that 
biomarker combinations improve prediction of future ovarian cancer diagnosis, the absolute 
gain in classification appeared to be small in our data, and a similar observation was made in 
the PLCO cohort (19). Thus, the addition of biomarkers can improve the discriminatory 
ability of CA125 but current biomarkers may not improve performance to the degree 
required for population screening.
Analyses in the PLCO study as well as ours, show substantial discrepancy between the often 
promising findings from Phase-II discovery studies based on clinical case-control 
comparisons and their lack of replication in prospective evaluations based on pre-diagnostic 
blood samples. This observation has triggered recommendations that greater care should be 
taken in selecting the appropriate sample set for screening biomarker discovery. In 
particular, it was recommended that prospective cohort studies should be used for new 
biomarker discovery rather than simply validation of known candidate biomarkers (32-34). 
One advantage of such an approach would be that it ensures rigorous internal validity for the 
evaluation of systematic differences between case and control subjects. Another possible 
advantage of the prospective design is that, by focusing on blood samples collected months 
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prior to cancer diagnosis, one would avoid a bias towards markers exclusively associated 
with advanced disease (32). While attractive from a methodological perspective, however, 
the use of prospective cohorts for biomarker discovery may have several limitations in 
practice. In our study, among 366,521 women mostly aged 35-70 at blood donation, there 
was an annual incidence of about 35 ovarian cancer cases. Thus, assuming an early detection 
time window of 6-18 months prior to diagnosis (excluding the first 6 months of follow-up to 
reduce the presence of advanced disease), studies for marker discovery would be based on a 
very limited, yet etiologically diverse sample set. This basic observation illustrates that even 
very large prospective cohorts may not have a sufficient number of cases for biomarker 
discovery studies focusing on early stage disease. Moreover, as already noted, the tumor 
grade and stage at the time of blood sampling would remain unknown. Therefore, 
uncertainty will remain as to whether those patients whose tumor would have had elevated 
biomarkers 6-18 months prior to diagnosis (and hence potentially detected) would actually 
benefit from detection at that timepoint. In light of these limitations, we believe that, as a 
complement to prospective cohort studies, bio-banking initiatives in large clinical networks 
will remain needed for the collection of samples especially from well-characterized early-
stage patients to allow large-scale comparisons with samples from cancer-free individuals.
In summary, CA125 and HE4 continue to hold potential for ovarian cancer screening but 
lack sensitivity and specificity needed to detect early stage disease. New biorepositories of 
early stage disease and matched controls are needed to identify novel markers that focus on 
the disease timepoint where intervention can make the biggest improvement in mortality and 
morbidity.
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Statement of Translational Relevance
Ovarian cancer is a leading cause of cancer-related death among women. About 60% of 
ovarian cancers are diagnosed at late stage, when 5-year survival is less than 30% in 
contrast to 90% for local disease. Biomarkers for early detection are urgently needed to 
improve survival. Using blood samples of ovarian cancer cases and cancer-free control 
subjects from the European EPIC study, we examined the prospective diagnostic capacity 
of CA125, HE4, CA72.4 and CA15.3. All markers were significantly elevated many 
months before clinical manifestation of ovarian cancer. The best discrimination between 
cases and controls was within six months of diagnosis for CA125 (C-statistic=0.92) and 
HE4 (0.84). Marker performance declined with longer time between blood draw and 
diagnosis and for earlier staged disease. Combining CA125 with HE4 and further 
markers modestly improved discrimination. Our study confirms CA125 as the single best 
marker for the early detection of invasive epithelial ovarian cancer.
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Locally estimated scatterplot smoothing (Loess) curves over time prior to diagnosis. The 
blue line represents controls, the green line stage I cases, the yellow line stage II cases, and 
the red line stage III/IV cases.
For CA125 and CA15.3 data are shown only for lag-times between blood donation and 
cancer diagnosis up to 6 years.
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ROC curves and C-statistics for diagnosis ≤6 months, ≤12 months, 1-2 years and 2-3 years 
after blood collection
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Table 1
Characteristics of cases and controls in the EPIC cohort (median (min-max) or n (%))
Cases (n=810) Controls (n=1,939) p-Value
Age at blood draw, yrs 56.4 (29.9-80.7) 56.7 (30.1-79.3)
Age at blood draw, yrs
    <50 166 (20%) 405 (21%)
    50-55 187 (23%) 430 (22%)
    55-60 183 (23%) 430 (22%)
    60-65 185 (23%) 445 (23%)
    ≥65 89 (11%) 229 (12%)
Menopausal status
    Pre 132 (16%) 329 (17%)
    Peri
a 118 (15%) 274 (14%)
    Post 560 (69%) 1 336 (69%)
BMI 25.1 (17.2-45.4) 25.0 (14.9-50.6) 0.03
Smoking
b 0.12
    Never 432 (55%) 1 103 (58%)
    Former 185 (23%) 435 (23%)
    Current 177 (22%) 368 (19%)
Parous
b 617 (83%) 1 585 (89%) <0.0001
Number of children
b, c 0.31
    1 114 (19%) 277 (18%)
    2 297 (49%) 733 (48%
    >2 191 (32%) 531 (34%)
Hysterectomy
b 69 (11%) 176 (11%) 0.35
Case characteristics
Age at diagnosis 62.7 (30.6-86.5) -
Lag time (years) 6.1 (0-16.0) -
Cancer site
    Ovary 752 (93%) -
    Fallopian tube 33 (4%) -
    Peritoneum 25 (3%) -
Histology
    Serous 445 (55%) -
    Mucinous 58 (7%) -
    Endometrioid 96 (12%) -
    Clear cell 37 (4%) -
    NOS 136 (17%) -
    Other 38 (5%) -
Cancer grade
b
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Cases (n=810) Controls (n=1,939) p-Value
    Well differentiated 45 (9%) -
    Moderately differentiated 164 (35%) -
    Poorly differentiated / undifferentiated 264 (56%) -
Disease spread
b
    Localized (stage I) 115 (16%) -
    Regional (stage II) 128 (18%) -
    Metastatic (stage III/IV) 469 (66%) -
Marker
d
CA125 (U/mL) 27.6 (26.2-29.1) 20.2 (19.5-20.8) <0.0001
HE4 (pM) 29.1 (26.9-31.6) 18.9 (18.1-19.7) <0.0001
CA72.4 (U/mL)
e 5.5 (4.4-6.9) 2.4 (2.0-2.9) 0.004
CA15.3 (mIU/mL) 624.3 (600.3-649.2) 600.6 (585.6-616.0) 0.10
a
Defined as women between the ages of 42 and 55 years who have missing or incomplete questionnaire data, reported irregular menstrual cycles in 
the past 12 months or had a prior hysterectomy without oophorectomy
b
Data were missing on smoking for 16 cases and 33 controls, on parity for 64 cases and 151 controls, on number of children for 79 cases and 195 
controls, on hysterectomy for 178 cases and 436 controls, on cancer grade for 337 cases, on the dualistic model for 385 cases, and on disease 
spread for 98 cases.
c
Among parous women (n=2 202)
d
Presented as geometric mean (5th-95th percentile); Data were missing on CA125 for 3 cases and 12 controls, on HE4 for 2 controls, on CA72.4 
for 2 controls, and on CA15.3 for 6 cases and 19 controls.
e
Based on 67 (34%) cases and 109 (15%) controls with CA72.4 above the detection limit (CA72.4 was measured in 197 cases and 725 controls).
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Table 2
Sensitivity at 95% and 98% specificity and C-statistics by time between blood draw and diagnosis
# of Sets Sensitivity at 95% specificity Sensitivity at 98% specificity C-statistic (95%-CI) pHet
a
CA125 Cut-point: 56.64 U/mL Cut-point: 77.92 U/mL
Overall 807 0.14 (0.11-0.18) 0.10 (0.07-0.13) 0.58 (0.56-0.60)
    ≤ 6 months 26 0.81 (0.61-0.92) 0.77 (0.57-0.89) 0.92 (0.86-0.98)
    ≤ 12 months 61 0.59 (0.46-0.71) 0.52 (0.39-0.66) 0.82 (0.76-0.88)
    > 1 to 2 years 75 0.27 (0.18-0.38) 0.20 (0.12-0.31) 0.72 (0.65-0.78)
    > 2 to 3 years 58 0.10 (0.05-0.22) 0.03 (0.01-0.13) 0.56 (0.48-0.64)
    > 3-6 years 200 0.08 (0.05-0.13) 0.06 (0.03-0.11) 0.55 (0.50-0.60)
    > 6 years 413 0.09 (0.06-0.13) 0.04 (0.02-0.07) 0.54 (0.51-0.57)
Stage I 115 0.16 (0.1-0.24) 0.10 (0.06-0.18) 0.58 (0.51-0.64)
    ≤ 6 months 7 0.43 (0.14-0.77) 0.29 (0.07-0.68) 0.69 (0.47-0.91)
    ≤ 12 months 16 0.38 (0.18-0.63) 0.31 (0.13-0.57) 0.65 (0.49-0.80)
    > 1 to 2 years 7 0.14 (0.02-0.58) 0.14 (0.02-0.58) 0.55 (0.31-0.80)
    > 2 to 3 years 9 0 (0-0.34) 0 (0-0.34) 0.52 (0.30-0.74)
    > 3-6 years 32 0.13 (0.05-0.29) 0.09 (0.03-0.26) 0.60 (0.48-0.72)
    > 6 years 51 0.14 (0.07-0.26) 0.06 (0.02-0.17) 0.57 (0.47-0.66)
Stage II 128 0.14 (0.09-0.22) 0.09 (0.05-0.16) 0.61 (0.55-0.67)
    ≤ 6 months 1
    ≤ 12 months 8 0.75 (0.38-0.94) 0.50 (0.20-0.80) 0.91 (0.79-1.02)
    > 1 to 2 years 10 0.30 (0.10-0.63) 0.30 (0.10-0.63) 0.75 (0.58-0.93)
    > 2 to 3 years 11 0.09 (0.01-0.44) 0 (0-0.28) 0.66 (0.48-0.84)
    > 3-6 years 37 0.05 (0.01-0.19) 0.05 (0.01-0.20) 0.53 (0.41-0.64)
    > 6 years 62 0.10 (0.04-0.20) 0.05 (0.02-0.14) 0.57 (0.48-0.66)
Stage III/IV 467 0.14 (0.10-0.18) 0.09 (0.06-0.13) 0.57 (0.54-0.60) 0.26
    ≤ 6 months 15 0.93 (0.65-0.99) 0.93 (0.64-0.99) 0.96 (0.92-1.01) 0.09
    ≤ 12 months 31 0.68 (0.49-0.82) 0.65 (0.46-0.80) 0.87 (0.80-0.94) 0.045
    > 1 to 2 years 50 0.26 (0.15-0.40) 0.16 (0.08-0.30) 0.72 (0.64-0.80) 0.77
    > 2 to 3 years 36 0.14 (0.06-0.30) 0.06 (0.01-0.20) 0.57 (0.46-0.67) 0.20
    > 3-6 years 106 0.07 (0.03-0.13) 0.04 (0.01-0.10) 0.52 (0.45-0.59) 0.68
    > 6 years 244 0.07 (0.05-0.12) 0.04 (0.02-0.07) 0.53 (0.48-0.57) 0.34
HE4 Cut-point: 39.41 pM Cut-point: 54.01 pM
Overall 197 0.24 (0.17-0.32) 0.18 (0.11-0.27) 0.67 (0.63-0.71)
    ≤ 6 months 27 0.67 (0.46-0.82) 0.59 (0.39-0.77) 0.84 (0.76-0.92)
    ≤ 12 months 62 0.48 (0.35-0.62) 0.39 (0.25-0.54) 0.79 (0.73-0.85)
    > 1 to 2 years 76 0.17 (0.10-0.28) 0.14 (0.07-0.26) 0.65 (0.58-0.72)
    > 2 to 3 years 59 0.07 (0.02-0.17) 0 (0-0.06) 0.56 (0.48-0.65)
Stage I 32 0.13 (0.05-0.30) 0.09 (0.03-0.27) 0.59 (0.48-0.70)
    ≤ 6 months 7 0.14 (0.02-0.59) 0.14 (0.02-0.59) 0.51 (0.27-0.76)
    ≤ 12 months 16 0.19 (0.06-0.45) 0.19 (0.06-0.46) 0.57 (0.41-0.73)
    > 1 to 2 years 7 0 (0-0.41) 0 (0-0.41) 0.52 (0.28-0.77)
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# of Sets Sensitivity at 95% specificity Sensitivity at 98% specificity C-statistic (95%-CI) pHet
a
    > 2 to 3 years 9 0.11 (0.02-0.51) 0 (0-0.34) 0.71 (0.52-0.90)
Stage II 29 0.10 (0.03-0.28) 0.07 (0.02-0.25) 0.68 (0.57-0.79)
    ≤ 6 months 1
    ≤ 12 months 8 0.25 (0.06-0.63) 0.13 (0.02-0.55) 0.72 (0.52-0.92)
    > 1 to 2 years 10 0.10 (0.01-0.47) 0.10 (0.01-0.48) 0.66 (0.46-0.85)
    > 2 to 3 years 11 0 (0-0.28) 0 (0-0.28) 0.67 (0.49-0.85)
Stage III/IV 119 0.31 (0.22-0.42) 0.23 (0.14-0.34) 0.69 (0.64-0.75) 0.34
    ≤ 6 months 16 0.88 (0.61-0.97) 0.75 (0.48-0.91) 0.97 (0.93-1.01) 0.007
    ≤ 12 months 32 0.72 (0.53-0.85) 0.56 (0.37-0.74) 0.92 (0.87-0.97) 0.01
    > 1 to 2 years 50 0.22 (0.12-0.37) 0.18 (0.09-0.33) 0.67 (0.58-0.75) 0.07
    > 2 to 3 years 37 0.08 (0.03-0.23) 0 (0-0.09) 0.53 (0.42-0.63) 0.09
CA72.4 Cut-point: 2.46 U/mL Cut-point: 5.96 U/mL
Overall 197 0.23 (0.17-0.32) 0.13 (0.08-0.21) 0.61 (0.56-0.65)
    ≤ 6 months 27 0.56 (0.36-0.74) 0.37 (0.20-0.58) 0.77 (0.68-0.87)
    ≤ 12 months 62 0.45 (0.32-0.59) 0.26 (0.15-0.40) 0.72 (0.65-0.79)
    > 1 to 2 years 76 0.20 (0.12-0.32) 0.11 (0.05-0.21) 0.61 (0.54-0.68)
    > 2 to 3 years 59 0.05 (0.02-0.15) 0.02 (0-0.12) 0.53 (0.44-0.61)
Stage I 32 0.22 (0.10-0.40) 0.06 (0.01-0.23) 0.58 (0.47-0.69)
    ≤ 6 months 7 0.14 (0.02-0.59) 0 (0-0.41) 0.61 (0.37-0.85)
    ≤ 12 months 16 0.25 (0.09-0.52) 0.13 (0.03-0.4) 0.61 (0.46-0.77)
    > 1 to 2 years 7 0.14 (0.02-0.59) 0 (0-0.41) 0.57 (0.32-0.81)
    > 2 to 3 years 9 0.22 (0.05-0.58) 0 (0-0.34) 0.52 (0.30-0.74)
Stage II 29 0.21 (0.09-0.40) 0.14 (0.05-0.33) 0.59 (0.47-0.71)
    ≤ 6 months 1
    ≤ 12 months 8 0.38 (0.12-0.72) 0.25 (0.06-0.63) 0.69 (0.48-0.90)
    > 1 to 2 years 10 0.30 (0.10-0.63) 0.20 (0.05-0.55) 0.67 (0.48-0.86)
    > 2 to 3 years 11 0 (0-0.28) 0 (0-0.28) 0.56 (0.37-0.76)
Stage III/IV 119 0.24 (0.16-0.34) 0.14 (0.08-0.24) 0.61 (0.56-0.67) 0.40
    ≤ 6 months 16 0.69 (0.43-0.87) 0.50 (0.26-0.74) 0.80 (0.68-0.92) 0.29
    ≤ 12 months 32 0.56 (0.38-0.73) 0.34 (0.19-0.54) 0.76 (0.67-0.85) 0.80
    > 1 to 2 years 50 0.18 (0.09-0.32) 0.10 (0.04-0.23) 0.61 (0.52-0.70) 0.35
    > 2 to 3 years 37 0.03 (0-0.17) 0.03 (0-0.18) 0.52 (0.41-0.62) 0.39
CA15.3 Cut-point: 1,372 mIU/mL Cut-point: 1,610 mIU/mL
Overall 804 0.07 (0.05-0.09) 0.04 (0.02-0.06) 0.51 (0.49-0.54)
    ≤ 6 months 26 0.31 (0.16-0.51) 0.23 (0.11-0.43) 0.73 (0.62-0.84)
    ≤ 12 months 61 0.16 (0.09-0.28) 0.13 (0.06-0.25) 0.58 (0.50-0.66)
    > 1 to 2 years 74 0.14 (0.07-0.24) 0.08 (0.04-0.17) 0.52 (0.45-0.60)
    > 2 to 3 years 58 0 (0-0.06) 0 (0-0.06) 0.54 (0.45-0.62)
    > 3-6 years 200 0.04 (0.02-0.08) 0.02 (0-0.05) 0.53 (0.48-0.58)
    > 6 years 411 0.06 (0.04-0.09) 0.03 (0.02-0.05) 0.51 (0.48-0.55)
Stage I 114 0.07 (0.03-0.14) 0.04 (0.02-0.11) 0.52 (0.46-0.59)
    ≤ 6 months 7 0.29 (0.07-0.68) 0 (0-0.41) 0.78 (0.59-0.97)
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    ≤ 12 months 16 0.19 (0.06-0.45) 0.06 (0.01-0.34) 0.66 (0.51-0.81)
    > 1 to 2 years 6 0.17 (0.02-0.63) 0.17 (0.02-0.63) 0.67 (0.42-0.91)
    > 2 to 3 years 9 0 (0-0.34) 0 (0-0.34) 0.56 (0.34-0.77)
    > 3-6 years 32 0.03 (0-0.19) 0 (0-0.11) 0.61 (0.49-0.73)
    > 6 years 51 0.06 (0.02-0.17) 0.06 (0.02-0.17) 0.55 (0.46-0.65)
Stage II 128 0.06 (0.03-0.12) 0.02 (0-0.06) 0.54 (0.49-0.6)
    ≤ 6 months 1
    ≤ 12 months 8 0 (0-0.37) 0 (0-0.37) 0.52 (0.29-0.75)
    > 1 to 2 years 10 0.30 (0.10-0.63) 0.1 (0.01-0.47) 0.59 (0.39-0.79)
    > 2 to 3 years 11 0 (0-0.28) 0 (0-0.28) 0.50 (0.30-0.69)
    > 3-6 years 37 0 (0-0.09) 0 (0-0.09) 0.56 (0.44-0.67)
    > 6 years 62 0.08 (0.03-0.18) 0.02 (0-0.11) 0.55 (0.46-0.64)
Stage III/IV 465 0.06 (0.04-0.09) 0.04 (0.02-0.07) 0.50 (0.46-0.53) 0.37
    ≤ 6 months 15 0.27 (0.10-0.54) 0.27 (0.10-0.54) 0.71 (0.57-0.86) 0.51
    ≤ 12 months 31 0.16 (0.07-0.34) 0.16 (0.07-0.34) 0.55 (0.43-0.66) 0.64
    > 1 to 2 years 50 0.10 (0.04-0.22) 0.08 (0.03-0.20) 0.50 (0.41-0.59) 0.16
    > 2 to 3 years 36 0 (0-0.1) 0 (0-0.1) 0.56 (0.45-0.67) 0.32
    > 3-6 years 106 0.04 (0.01-0.10) 0.02 (0-0.07) 0.50 (0.44-0.57) 0.16
    > 6 years 242 0.06 (0.04-0.10) 0.03 (0.01-0.06) 0.53 (0.48-0.57) 0.22
a
Heterogeneity of discrimination capacity by tumor stage was examined with likelihood-ratio tests comparing the model fit for logistic regression 
models with and without corresponding interaction terms
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